Ganoderma: The mushroom of immortality

El Mansy SM

Postgraduate student at Zoology Department, Faculty of Science, Suez Canal University, Ismailia 45122, Egypt.

El Mansy SM 2019 – Ganoderma: The mushroom of immortality. Microbial Biosystems 4(1), 45-57.

Abstract

Ganoderma is the genus from order Aphyllophorales with more than 300 species. Ganoderma contains various compound that showed many biological activities e.g. enhancer of immune system, antitumor, antimicrobial, anti-inflammatory, antioxidant and acetyl cholinesterase inhibitory action. These bioactive compounds related to the triterpenoids and polysaccharides classes. Proteins, lipids, phenols, sterols, and others, are also recorded. Ganoderma is currently an important source in the pharmaceutical industry and is one of the most promising projects in the world of food and medicine, which is being highlighted these days. In Egypt seven species of Ganoderma were recorded by Abdel-Azeem (2018). Among cultivated mushrooms, G. lucidum is unique in that its pharmaceutical rather than nutritional value is paramount. A variety of commercial G. lucidum products are available in various forms, such as powders, dietary supplements, and tea. These are produced from different parts of the mushroom, including mycelia, spores, and fruit body. The commercial cultivation of Ganoderma in Egypt not started yet. In this article the most important bioactive materials produced by Ganoderma, their applications and business opportunity in Egypt will be discussed.

Keywords – Egypt, Lingzhi, Triterpens, Polysaccharides, Anti-HIV, Anti-cancer

Introduction

Ganoderma is a historical fungus that used for promoting health and longevity in China, Japan, and other Asian countries. It is a large, dark mushroom with a glossy exterior and a woody texture. The Latin word lucidus means “shiny” or “brilliant” and refers to the brown varnished appearance of the surface of the mushroom (Fig. 1). In China, G. lucidum is called lingzhi, whereas in Japan the name for the Ganodermataceae family is rishi or mannentake.

The name lingzhi represents a combination of spiritual potency and essence of immortality, and is regarded as the “herb of spiritual potency,” symbolizing success, well-being, divine power, and longevity. Among cultivated mushrooms, G. lucidum is unique in that its pharmaceutical rather than nutritional value is paramount. A variety of commercial Ganoderma products are available in various forms, such as powders, dietary supplements, and tea. These are produced from different parts of the mushroom, including mycelia, spores, and fruit body.

The specific applications and attributed health benefits of lingzhi include control of blood glucose levels, modulation of the immune system, hepatoprotection, bacteriostasis, and more. The various beliefs regarding the health benefits of it are based largely on anecdotal evidence, traditional use, and cultural mores. However, recent reports provide scientific support to some of the ancient claims of the health benefits of lingzhi (Wachtel-Galor and Benzi 2011). The family Ganodermataceae describes polypore basidiomycetous fungi having a double-walled
basidiospore (Donk 1964). In all, 219 species within the family have been assigned to the genus *Ganoderma*, of which *G. lucidum* is the species type (Moncalvo 2000). Basidiocarps of this genus have a laccate (shiny) surface that is associated with the presence of thick-walled pilocystidia embedded in an extracellular melanin matrix (Moncalvo 2000).

**Fig 1** – Basidiomata of *Ganoderma lucidum* (Courtesy of Prof. Ahmed M. Abdel-Azeem).

*Ganoderma* species are found all over the world, and different characteristics, such as shape and color (red, black, blue/green, white, yellow, and purple) of the fruit body, host specificity, and geographical origin, are used to identify individual members of the species (Zhao and Zhang 1994; Woo et al. 1999; Upton 2000).

In Egypt Abdel-Azeem (2018) recorded seven species of *Ganoderma* namely *G. Adspersum* (Schulzer) Donk, *G. applanatum* (Pers.) Pat., *G. carnosum* Pat., *G. colossus* (Fr.) C.F. Baker, *G. lucidum* (Curtis) P. Karst., *G. mbrekobenum* E.C. Otto, Blanchette, Held, C.W. Barnes & Obodai, and *G. resinaceum* Boud.. Recently Abdel-Azeem and Nafady (2019) recorded *Tomophagus colossus* (= *G. colossus*) as a new record in Egypt.

**Major bioactive components in Ganoderma**

*Ganoderma* contains a wide variety of bioactive molecules, such as terpenoids (Fig. 2), steroids, phenols, nucleotides and their derivatives, glycoproteins, and polysaccharides. Mushroom proteins contain all the essential amino acids and are especially rich in lysine and leucine. The low total fat content and high proportion of polyunsaturated fatty acids relative to the total fatty acids of mushrooms are considered significant contributors to the health value of mushrooms (Chang and Buswell 1996; Borchers et al. 1999; Sanodiya et al. 2009).
**Fig 2** – General structure of terpenoids in *Ganoderma lucidum*.

**Triterpenes**

The Terpenes are a class of naturally occurring compounds whose carbon skeletons are composed of one or more isoprene C5 units. Terpenes have also been found to have anti-inflammatory, antitumorigenic, and hypolipidemic activity. Terpenes in *Ginkgo biloba*, rosemary (*Rosemarinus officinalis*), and ginseng (*Panax ginseng*) are reported to contribute to the health-promoting effects of these herbs (Mahato and Sen 1997; Mashour *et al.* 1998; Haralampidis *et al.* 2002).

| Compounds         | R1 | R2 | R3 |
|-------------------|----|----|----|
| Ganoderic acid A  | 0  | H₂ |    |
| Ganoderic acid B  |    | H₂ | 0  |
| Ganoderic acid C1 | 0  | H₂ | 0  |
| Ganoderic acid C2 |    | H₂ | 0  |
| Ganoderic acid G  |    |    |    |
| Ganoderic acid γ* | 0  | H₂ |    |

*Structure of side chain:*
The triterpenes (Fig. 3) are a subclass of terpenes and have a skeleton of C30 and have molecular weights ranging from 400 to 600 kDa and their chemical structure is complex and highly oxidized (Mahato and Sen 1997; Zhou et al. 2007). In *Ganoderma* the chemical structure of the triterpenes is based on lanostane, which is a metabolite of lanosterol, the biosynthesis of which is based on cyclization of squalene (Haralampidis et al. 2002). Extraction of triterpenes is usually done by means of methanol, ethanol, acetone, chloroform, ether, or a mixture of these solvents. The extracts can be further purified by various separation methods, including normal and reverse-phase HPLC (Chen et al. 1999; Su et al. 2001).

The first triterpenes isolated is from *G. lucidum* called the ganoderic acids A and B, which were identified by Kubota et al. (1982). Since then, more than 100 triterpenes with known chemical compositions and molecular configurations have been reported to occur in *G. lucidum*. Among them, more than 50 were found to be new and unique to this fungus. The vast majority are ganoderic and lucidenic acids, but other triterpenes such as ganoderals, ganoderiols, and

**Fig 3** – Some examples of triterpenoids extracted from *Ganoderma*. 
ganodermic acids have also been identified (Nishitoba et al. 1984; Sato et al. 1986; Budavari 1989; Gonzalez et al. 1999; Ma et al. 2002; Akihisa et al. 2007; Zhou et al. 2007; Jiang et al. 2008; Chen et al. 2010).

**Antitumor anticancer activity**

The triterpene extracts of *G. lucidum* are known to induce apoptosis of multiple human cancer cell lines. However, the cytotoxic activity of triterpenes varied significantly across different subtypes of triterpenes. Most triterpenoids extracted and identified from *Ganoderma* have shown robust biological activities. The ganodermic acids isolated from *Ganoderma* have shown antiviral, anticancer, antioxidant, hepatoprotective, cytotoxic, antiplatelet aggregation, and inhibition of histamine release and hypocholesterolemic activities. The most abundant triterpenic acid from *G. lucidum* is GA T which shows significant anticancer activity both in vivo and in vitro experiments. GA has been found to inhibit tumor invasion by inhibiting matrix metalloproteinase (MMP)-9 expressions.

Another triterpenic acid GAD has been shown to directly bind to 14-3-3ζ protein and this binding may contribute to the facilitation of apoptosis observed in human epithelial cell line (HeLa) cell. The triterpene extracts identified from *G. lucidum* and other *Ganoderma* species have shown antitumor property under in vivo conditions. The carcinogenic effects shown by various types of extracts from *G. lucidum* include various cancer cell lines (breast, colon, lung, pancreas, prostate, and skin). The known mechanisms through which the extracts of *G. lucidum* exhibit antitumor activities include direct inhibition of cell proliferation through cancer-specific cell cycle arrest and apoptosis. Various other studies have also shown that the triterpene extracts of *G. lucidum* have antioxidant activity and have the potential to reduce oxidative damage by directly scavenging free radicals generated in the cell due to the increase in the activity of superoxide dismutase and catalase which are enzymes involved in removing harmful free radicals and ROS. Smina *et al.* (2011) revealed in mice that triterpenes from *G. lucidum* showed antioxidant activity which may be due to increased activity of antioxidant enzyme sand they further observed that total terpenes from *G. lucidum* prevent radiation-induced DNA damage and apoptosis in splenic lymphocytes of mice under in vitro conditions. In a recent study carried by by Smina *et al.* (2016), total triterpenes from *G. lucidum* were highly effective in reducing the levels of lipid peroxidation and protein oxidation to near normal values in both liver and brain tissues in Swiss albino mice under in vivo conditions. Total triterpenes, when administered under vivo conditions, were also found to be successful in restoring the antioxidant enzyme activities and glutathione level in liver and brain of irradiated mice. Administration of total triterpenes, before radiation exposure, significantly decreased the DNA strand breaks.

**Anti-Viral activity**

El-Mekkawy *et al.* (1998) assayed 13 compounds for anti-HIV activity isolated from *G. lucidum*. El Dine *et al.* (2008) observed anti-HIV-1 protease activity of triterpenoids from *G. colosseum*. The inhibitory activity of triterpenoids isolated from *Ganoderma* species against HIV has also been reported by Cassels and Asencio (2011).

The ganoderic acid isolated from *G. lucidum* showed inhibitory effects on the replication of hepatitis B virus (HBV) in HepG2215 cells (HepG2- HBV-producing cell line) over 8 days. Production of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) were, respectively, 20% and 44% of controls without ganoderic acid treatment (Li and Wang 2006).

49
Anti-inflammatory potential

In the present study we evaluated the anti-inflammatory effects of the triterpene extract from G. lucidum (GLT) in LPS-stimulated macrophages. Here we show that GLT markedly suppressed the secretion of inflammatory cytokine tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and inflammatory mediator nitric oxide (NO) and prostaglandin E2 (PGE2) from lipopolysaccharide (LPS)-stimulated murine RAW264.7 cells. GLT also down-regulated LPS-dependent expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) in RAW264.7 cells. The anti-inflammatory effects of GLT were mediated by the inhibition of transcription factor NF-κB as demonstrated by decreased NF-κB-DNA binding activity, and the suppression of p65 phosphorylation in LPS-stimulated macrophages treated with GLT. Moreover, GLT inhibited LPS-dependent AP-1-DNA binding activity and down-regulated expression of AP-1 subunit c-Jun. In addition, GLT suppressed the activity of MAP kinases as observed by the down-regulation of LPS-induced phosphorylation of ERK1/2 and JNK but not p38. In vivo experiments clearly demonstrated that GLT also inhibited the production of TNF-α and IL-6 in LPS-induced endotoxemic mice. Apart from its anti-inflammatory activity, GLT suppressed cell proliferation of RAW264.7 cells through cell cycle arrest at G0/G1–G2M, which was mediated by the down-regulation of expression of cell cycle regulatory proteins cyclin D1, CDK4 and cyclin B1, respectively. In conclusion, the anti-inflammatory and anti-proliferative effects of GLT on macrophages are mediated through the inhibition of NF-κB and AP-1 signaling pathways. (Dudhgaonkar s. et al 2009)

Polysaccharides extracted from Ganoderma

Various polysaccharides have been extracted from the fruit body, spores, and mycelia of Ganoderma. They are produced by fungal mycelia cultured in fermenters and can differ in their sugar and peptide compositions and molecular weight. G. lucidum polysaccharides (GL-PSs) are reported to exhibit a broad range of bioactivities, including anti-inflammatory, hypoglycemic, antiulcer, antitumorogenic, and immunostimulating effects (Miyazaki and Nishijima 1981; Hikino et al. 1985; Tomoda et al. 1986; Bao et al. 2001; Wachtel-Galor et al. 2004). Polysaccharides are normally obtained from the mushroom by extraction with hot water followed by precipitation with ethanol or methanol, but they can also be extracted with water and alkali. Structural analyses of GL-PSs indicate that glucose is their major sugar component (Bao et al. 2001; Wang et al. 2002). However, GL-PSs are heteropolymers and can also contain xylose, mannose, galactose, and fructose in different conformations, including 1–3, 1–4, and 1–6-linked β and α-D (or L)-substitutions (Lee et al. 1999; Bao et al. 2002).

Branching conformation and solubility characteristics are said to affect the antitumorogenic properties of these polysaccharides (Bao et al. 2001; Zhang et al. 2001). The mushroom also consists of a matrix of the polysaccharide chitin, which is largely indigestible by the human body and is partly responsible for the physical hardness of the mushroom (Upton 2000).

Numerous refined polysaccharide preparations extracted from G. lucidum are now marketed as over-the-counter treatment for chronic diseases, including cancer and liver disease (Gao et al. 2003). Various bioactive peptidoglycans have also been isolated from G. lucidum, including G. lucidum proteoglycan (GLPG; with antiviral activity; Li et al. 2005), G. lucidum immunomodulating substance (GLIS; Ji et al. 2007), PGY (a water-soluble glycopeptide fractionated and purified from aqueous extracts of G. lucidum fruit bodies; Wu and Wang 2009), GL-PS peptide (GL-PP; Ho et al. 2007), and F3 (a fructose-containing glycoprotein fraction; Chien et al. 2004).
Other beneficial components extracted from *Ganoderma*

Phosphorus, sulfur, potassium, calcium, and magnesium are their main mineral components. Iron, sodium, zinc, copper, manganese, and strontium were also detected in lower amounts, as were the heavy metals lead, cadmium, and mercury (Chen et al. 1998). Significantly, no cadmium or mercury was detected in these samples. *G. lucidum* can also contain up to 72 μg/g dry weight of selenium and can bio transform 20–30% of inorganic selenium present in the growth substrate into selenium-containing proteins (Du et al. 2008).

Germanium was fifth highest in terms of concentration (489 μg/g) among the minerals detected in *G. lucidum* fruit bodies collected from the wild (Chiu et al. 2000). This mineral is also present in the order of parts per billion in many plant-based foods, including ginseng, aloe, and garlic (Mino et al. 1980). Although germanium is not an essential element, at low doses, it has been credited with immunopotentiating, antitumor, antioxidant, and antimutagenic activities (Kolesnikova et al. 1997). *G. lucidum* contains some other compounds that may contribute to its reported medicinal effect, such as proteins and lectins.

The protein content of dried *G. lucidum* was found to be around 7–8%, which is lower than that of many other mushrooms (Chang and Buswell 1996; Mau et al. 2001). Bioactive proteins are reported to contribute to the medicinal properties of *G. lucidum*, including LZ-8, an immunosuppressive protein purified from the mycelia (Van Der Hem et al. 1995); a peptide preparation (GLP) exhibiting hepatoprotective and antioxidant activities (Sun et al. 2004) and a 15-kDa antifungal protein, ganodermin, which is isolated from *G. lucidum* fruiting bodies (Wang and Ng 2006).

The carbohydrate and crude fiber content of the dried mushroom was examined and found to be 26–28% and 59%, respectively (Mau et al. 2001). Lectins were also isolated from the fruit body and mycelium of the mushroom (Kawagishi et al. 1997), including a novel 114-kDa hexameric lectin, which was revealed to be a glycoprotein having 9.3% neutral sugar and showing hem agglutinating activity on pronase-treated human erythrocytes (Thakur et al. 2007). Lectins (from the Latin word legere, which means to pick up, choose) are non-enzymatic proteins or glycoproteins that bind carbohydrates. Many species of animals, plants, and microorganisms produce lectins, and they exhibit a wide range of functions. In animals, for example, lectins are involved in a variety of cellular processes and the functioning of the immune system (Wang et al. 1998).

Also Metalloprotease, which delays clotting time; ergosterol (provitamin D2); nucleosides; and nucleotides (adenosine and guanosine) (Wasser et al. 2005; Paterson 2006). Kim and Nho (2004) also described the isolation and physicochemical properties of a highly specific and effective reversible inhibitor of α-glucosidase, SKG-3, from *G. lucidum* fruit bodies. Furthermore, *G. lucidum* spores were reported to contain a mixture of several long-chain fatty acids that may contribute to the antitumor activity of the mushroom (Fukuzawa et al. 2008; Wachtel-Galor et al. 2011).

**Economic importance of *Ganoderma* mushroom**

Cultivation of the *Genoderma* mushroom in the countries of Asia is of great importance to its health benefits as well as the huge economic return from it. For a new business opportunity in Egypt, there are many factors which will help this industry to success, including the appropriate climate, spread of *Ganoderma* in the governorates of the Nile Delta region, the availability of suitable areas for cultivation (no need of special difficult preparations), the low cost and the most important factor are the studies and researchers who are able to develop this project and provide sufficient information to help the workers in it. The *Ganoderma* project can provide employment opportunities for young people, eldery and women for ease of operation, providing foreign currency where the kilogram sold for about 36 dollars, also opening a new market in the field of pharmaceutical industries. In addition, strengthening the market with a natural product has
enormous benefits as reishi coffee and tea both for prevention and treatment of diseases. For more details please read Mansour et al. (2018).

Conclusion

There is still little information available concerning the use of advanced fermentation techniques for obtaining *Ganoderma lucidum* mycelium and its valuable components in Egypt. A better understanding of its morphology and physiology is crucial for the development of large scale fermentation processes. Over the past two decades, the *Ganoderma* industry has developed greatly and today offers thousands of products to the markets. Despite the large market, there are problems with the industry which prevent it from establishing an effective market. In Egypt the world *Ganoderma* cultivation, products, industry and research is urgently needed.

Acknowledgements

The author would like to thank Prof. Ahmed M. Abdel-Azeem for suggesting the point of this review and his continuous support and the two unknown reviewers for their valuable suggestions.

References

Abdel-Azeem A.M. 2018. Fungi in Egypt: A galaxy to discover. The Second International Conference on Mycology in MENA (ICM-2018), Ismailia, Egypt, 16-18 October 2018. Abstract book pp. 22-24.

Abdel-Azeem A. M. and Nafady N. A. 2019. New records on the genus *Tomophagus* and *Battarrea* for mycobiota of Egypt. Current Research in Environmental and Applied Mycology 9(1): 77-84.

Akihisa T, Nakamura Y, Tagata M, Tokuda H., Yasukawa K., Uchiyama E. and Suzuki T.2007. Anti-inflammatory and anti-tumor-promoting effects of triterpene acids and sterols from the fungus *Ganoderma lucidum*. Chemistry and Biodiversity, 4(2): 224–31.

Bao X., Liu C., Fang J. and Li X. 2001. Structural and immunological studies of a major polysaccharide from spores of *Ganoderma lucidum*. Carbohydr Research, 332: 67–74.

Bao X., Wang X., Dong Q., Fang J. and Li X. 2002. Structural features of immunologically active polysaccharides from *Ganoderma lucidum*. Phytochemistry, 59: 175–181.

Bhat Z. A., Wani A. H., Bhat M. Y. and Malik A. R. 2019. Major bioactive Triterbenoids from *Ganoderma* species and their therapeutic activity. Asian journal of pharmaceutical and clinical research, 12(4): 22-33

Borchers A.T., Stern J.S., Hackman R.M., Keen C.L. and Gershwin M.E. 1999. Mushrooms, tumors and immunity. Proceedings of the Society for Experimental Biology and Medicine, 221: 281–93.

Budavari S.1999 .The Merck Index. elevan. New Jersey: Merck & Co., INC, p. 84.

Cao Y., Xu X., Liu S., Huang L. and Gu J. 2018. *Ganoderma*: A cancer immunotherapy review. Frontiers in Pharmacology, 9:1–14.

Cassels B.K. and Asencio M. 2011. Anti-HIV activity of natural triterpenoids and hemisynthetic derivatives 2004–2009. Phytochemistry Reviews, 10(4): 545-564

Celal B. 2019. Antioxidant and antimicrobial capacities of *Ganoderma lucidum*. MedCrave, 7 (1): 5-7.

Chang S. T. and Buswell J. A. 1996. Mushrooms nutriceuticals. World Journal of Microbiological Biotechnology,12: 473–6.

Chang Y.H., Yang J.S. and Yang J.L. 2009. *Ganoderma lucidum* extract promotes immune responses in normal BALB/c mice in vivo. In Vivo, 23:755–9.

Chen D. H, Shiou W. Y, Wang K. C, editors et al.1999. Chemotaxonomy of triterpenoid pattern of HPLC of *Ganoderma lucidum* and *Ganoderma tsugae*. Journal of the Chinese Chemical Society ,46: 47–51.
Chen J., Hudson E., Chi M.M., Chang A.S., Moley K.H., Hardie D.G. and Downs S.M. 2006. AMPK regulation of mouse oocyte meiotic resumption in vitro. Developmental Biology, 291(2): 227–238.

Chen T. Q, Li K. B, He X. J, Zhu P. G and Xu J. 1998. Micro-morphology, chemical components and identification of log-cultivated Ganoderma lucidum spore. Lu M, Gao K, Si H. -F, Chen M. -J Proc of Nanjing Symp Science & Cultivation of Mushrooms. p 214. Nanjing, China. JSTC-ISMS.

Chen Y, Bicker W, Wu J, Xie M. Y and Lindner W. 2010. Ganoderma species discrimination by dual-mode chromatographic fingerprinting: A study on stationary phase effects in hydrophilic interaction chromatography and reduction of sample misclassification rate by additional use of reversed-phase chromatography. Journal of Chromatography,1217(8):1255–65.

Chien C. M., Cheng J. L. and Chang W. T. 2004. Polysaccharides of Ganoderma lucidum alter cell immunophenotypic expression and enhance CD56+ NK-cell cytotoxicity in cord blood. Bioorganic and Medicinal Chemistry, 12(21): 5603–5609.

Chiu S.W., Wang Z.M., Leung T.M. and Moore D. 2000. Nutritional value of Ganoderma extract and assessment of its genotoxicity and antigenotoxicity using comet assays of mouse lymphocytes. Food Chemical Toxicology, 38 (2-3): 173–178.

Cilerdzic J., Stajic M. and Vukojevic J. 2018. Ganoderma lucidum - from tradition to modern medicine. Zbornik Matice Srpske Za Prirodne nauke Matica Srpska Journal for Natural Sciences, 133: 151–161.

Dudhaonkar S., Thyagarajan A. and Sliva D. 2009. Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. International Immunopharmacology, 9(11): 1272-1280.

Du M, Wang C, Hu X. C and Zhao G. 2008. Positive effect of selenium on the immune regulation activity of lingzhi or reishi medicinal mushroom, Ganoderma lucidum (W. Curt.: Fr.) P. Karst. (Aphyllophoromycetidae), proteins in vitro. International Journal of Medicinal Mushrooms, 10(4): 337–44.

El Dine R.S.I., El Halawany A. M., Ma C.M. and Hattori M. 2008. Anti-HIV-1 protease activity of lanostane triterpenes from the vietnamese mushroom Ganoderma colossum. Journal of Natural Products, 71(6):1022-1026.

El-Mekkawy S., Meselhy M.R, Nakamura N., Tezuka Y., Hattori M., Kakiuchi N., Shimotohno K., Kawahata T. and Otake T. 1998. Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum. Phytochemistry, 49(6): 1651–7.

Fukuzawa M., Yamaguchi R. and Hide I. 2008. Possible involvement of long chain fatty acids in the spores of Ganoderma lucidum (Reishi Houshi) to its anti-tumor activity. Biological and Pharmaceutical Bulletin, 31(10): 1933-1937.

Furusawa E., Chou S.C., Furusawa S., Hirazumi A. and Dang Y. 1992. Antitumour activity of Ganoderma lucidum, an edible mushroom, on intraperitoneally implanted Lewis lung carcinoma in synergenic mice. Phytotherapy Research, 6(6): 300 – 304.

Gao Y. and Zhou S. 2003. Cancer prevention and treatment by Ganoderma, a mushroom with medicinal properties. Food Reviews International, 19(3): 275-325

Gao Y. H., Zhou S. F., Jiang W. Q., Huang M. and Sai X. H. 2003. Effects of Ganopoly a Ganoderma lucidum polysaccharide extract on immune functions in advanced-stage cancer patients. Immunological Investigations, 32(3): 201–15.

Gonzalez A. G., Leon F., Rivera A., Munoz C. M. and Bermejo J. 1999. Lanostanoid triterpenes from Ganoderma lucidum. Journal of Natatural Products, 62(12): 1700–1701.

Haralampidis K., Trojanowska M. and Osbourn 2002. A. E. Biosynthesis of triterpenoid saponins in plants. Advances in Biochemical Engineering/Biotechnology, 75: 31–49.

Hikino H, Konno C, Mirin Y and Hayashi T. 1985. Isolation and hypoglycemic activity of ganoderans A and B, glycans of Ganoderma lucidum fruit bodies. Planata Medica,
51(4): 339–340.

Hong K. J., Dunn D. M., Shen C. L. and Pence B. C. 2004. Effects of *Ganoderma lucidum* on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells. Phytotherapy Research, 18(9):768–70.

Ho Y.W., Yeung J.S., Chiu P.K., Tang W.M., Lin Z.B., Man R.Y. and Lau C.S. 2007. *Ganoderma lucidum* polysaccharide peptide reduced the production of proinflammatory cytokines in activated rheumatoid synovial fibroblast. Molecular Cellular Biochemistry, 301(1-2): 173–9.

Hsiao W. L., Li Y. Q., Lee T. L., Li N., You M. M. and Chang S. T. 2004. Medicinal mushroom extracts inhibit ras-induced cell transformation and the inhibitory effect requires the presence of normal cells. Carcinogenesis, 25(7): 1177–1183.

Ji Z., Tang Q., Zhang J., Yang Y., Jia W. and Pan Y. 2007. Immunomodulation of RAW264.7 macrophages by GLIS, a proteopolysaccharide from *Ganoderma lucidum*. Journal of Ethnopharmacology, 112(3): 445–450.

Jiang J, Grieb B, Thyagarajan A. and Sliva D. 2008. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. International Journal of Molecular Medicine,21(5):577–84.

Kawagishi H., Mitsunaga S. I. and Yamawaki M.1997. A lectin from mycelia of the fungus *Ganoderma lucidum*. Phytochemistry, 44(1): 7–10.

Kolesnikova O. P., Tuzova M. N. and Kozlov V. A. 1997. Screening of immunoactive properties of alkanecarbonic acid derivatives and germanium-organic compounds in vivo. Immunologiya, 10: 36–8.

Kresnawaty I., Eris D.D., Mulyatni A.S. and Prakoso H. T. 2018. Inhibitory effect of phenolic acid on *Ganoderma boninense* enzyme as an approach on *Ganoderma* infection. IOP Conference Series: Earth and Environmental Science, 183(1): 1-7.

Kubota T., Asaka Y., Miura I. and Mori H. 1982. Structures of ganoderic acids A and B, two new lanostane type bitter triterpenes from *Ganoderma lucidum* (Fr.) Karst. Helvetica Chimica Acta,65(2): 611–9.

Lee J. M., Kwon H. and Jeong H. 2001. Inhibition of lipid peroxidation and oxidative DNA damage by *Ganoderma lucidum*. Phytotherapy Research, 15(3): 245–249.

Lee K. M., Lee S. Y.A. and Lee H. Y. 1999. Bistage control of pH for improving exopolysaccharide production from mycelia of *Ganoderma lucidum* in an air-lift fermentor. Journal Bioscience Bioengineering, 88(6): 646–650.

Li C. H., Chen P.Y. and Chang U.M. 2005. Ganoderic acid X, a lanostanoid triterpene, inhibits topoisomerases and induces apoptosis of cancer cells. Life Sciences, 77(3): 252–265.

Li Y. Q. and Wang S. F. 2006. Anti-hepatitis B activities of ganoderic acid from *Ganoderma lucidum*. Biotechnology Letters, 28(11): 837–841.

Li Y. Q. and Wang S. F. 2006. Anti-hepatitis B activities of ganoderic acid from *Ganoderma lucidum*. Biotechnology Letters, 28(11): 837–841.

Li Z., Liu J. and Zhao Y. 2005 Possible mechanism underlying the antitherpetic activity of a proteoglycan isolated from the mycelia of *Ganoderma lucidum* in vitro. J Biochemistry and Molecular Biology,38(1): 34–40.

Lin S. B., Li C. H., Lee S. S. and Kan L.S. 2003. Triterpene-enriched extracts from *Ganoderma lucidum* inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sciences, 72(21): 2381–2390.

Loyd A.L., Richter B.S., Jusino M.A., Truong C., Smith M.E., Blanchette R. A. and Smith J. A. 2018. Identifying the “Mushroom of immortality”: Assessing the *Ganoderma* species composition in commercial reishi products. Frontiers in Microbiology, 9: 1–14. DOI 10.3389/fmicb.

Ma B., Ren W., Zhou Y., Ma J., Ruan Y. and Wen C.N. 2011. Triterpenoids from the spores of
Ganoderma lucidum. North American Journal of Medical Sciences, 3(11): 495–498.
Ma J., Ye Q., Hua Y., Zhang D., Cooper R., Chang M.N., Chang J.Y. and Sun H.H. 2002. New lanostanoids from the mushroom Ganoderma lucidum. Journal of Natural Products, 65(1):72–75.
Mahato S.B. and Sen S. 1997. Advances in triterpenoid research, 1990-1994. Phytochemistry, 44: 1185–1236.
Mansour S. A., Abdel-Azeem A. M., Abdel-Azeem M. A. and Domecq I. M. 2018. Conserve the plant pathogenic fungus Ganoderma: An introduction to a business opportunity in Egypt. The Second International Conference on Mycology in MENA (ICM-2018), Ismailia, Egypt, 16-18 October 2018. Abstract book p. 69.
Mashour N. K., Lin G. I. and Frishman W. H. 1998. Herbal medicine for the treatment of cardiovascular disease: Clinical considerations. Archives of International Medicine, 158(20): 2225–2234.
Mau J. L., Lin H. C. and Chen C. C. 2001. Non-volatile components of several medicinal mushrooms. Food Research International, 34(6): 521–536.
Miyazaki T. and Nishijima M. 1981. Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum. Chemical Pharmaceutical Bulletin, 29(12): 3611–3616.
Moncalvo J. M., Lutzoni F. M., Rehner S.A., Johnson J. and Vilgalys R. 2000. Phylogenetic relationships of agaric fungi based on nuclear large subunit ribosomal DNA sequences. Biosystem Biology, 49(2): 278-305.
Navarro A. and Boveris A. 2009. Brain mitochondrial dysfunction and oxidative damage in Parkinson’s disease. Journal of Bioenergetics and Biomembranes, 41(6): 517–521.
Nishitoba T., Sato H., Kasai T., Kawagishi H. and Sakamura S. 1984. New bitter C27 and C30 terpenoids from fungus Ganoderma lucidum (Reishi). Agricultural and Biological Chemistry, 48(11): 2905-2907.
Oh K.W., Lee C.K., Kim Y.S., Eo S.K. and Han S S. 2000. Antiherpetic activities of acidic protein bound polysaccharide isolated from Ganoderma lucidum alone and in combination with Acyclovir and Vidarabine. Journal of Ethnopharmacology, 72(2): 221–237.
Ohno N, Miura N.N, Sugawara N, Tokunaka K, Kirigaya N. and Yadomae T. 1998. Immunomodulation by hot water and ethanol extracts of Ganoderma lucidum. Pharmaceutical and Pharmacological Letters, 4(8): 174–157.
Ooi V. E. and Liu F. 2000. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Current Medicinal Chemistry, 7(7): 715–729.
Park E. J, Ko G, Kim J. and Dong H. S. 1997. Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, Glycyrrhizin, and Pentoxifylline in rats with cirrhosis induced by biliary obstruction. Biological and Pharmaceutical Bulletin, 20(4): 417–420.
Paterson R. R. 2006. Ganoderma-a therapeutic fungal biofactory. Phytochemistry, 67(18): 1985–2001.
Ratnaprityas N. I., Hernayanti H., Andarwanti S., Ekowati N., Purwanti E.S. and Sukmawati D. 2018. Effects of Ganoderma lucidum Extract on Diabetic Rats. Biosaintifika: Journal of Biology and Biology Education, 10(3):642–647. DOI 10.15294.
Rupeshkumar M., Chetturi U., Jaikumar S., Rathibai M. and Paarakh P. M. 2016. Ganoderma lucidum: A review with special emphasis on the treatment of various cancer. Journal of Applied Pharmacy, 8(4): 1–5. DOI 10.21065/1920-4159.1000228.
Sanodiya B., Thakur G., Baghel R., Prasad G. and Bisen P. 2009. Ganoderma lucidum: A Potent Pharmacological Macrom fungus. Current Pharmaceutical Biotechnology, 10(8): 717–742. DOI 10.2174/138920109789978757.
Sato H., Nishitoba T., Shirasu S., Oda K. and Sakamura S. 1986. Ganoderiol A and B, new triterpenoids from the fungus Ganoderma lucidum (Reishi). Agricultural and Biological Chemistry, 50(11): 2887–2890.
Smina T. P., Agarwal S., Devasagayam T. P. A., Adhekari S., Janardhanan K. K. 2011. *Ganoderma lucidum* total triterpenes prevent radiation-induced DNA damage and apoptosis in splenic lymphocytes in vitro. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 726(2): 188-194.

Smina T. P., Joseph J. and Janardhanan K.K. 2016. *Ganoderma lucidum* total triterpenes prevent γ-radiation induced oxidative stress in Swiss albino mice in vivo. Redox Report, 21(6): 254-261.

Su C. H., Yang Y. Z., Ho H., Hu C. H. and Sheu M. T. 2001. High-performance liquid chromatographic analysis for the characterization of triterpenoids from *Ganoderma*. Journal of Chromatographic Science, 39(3): 93–100.

Sun J., He H. and Xie B. J. 2004. Novel antioxidant peptides from fermented mushroom *Ganoderma lucidum*. Journal of Agricultural and Food Chemistry, 52(21): 6646–6652.

Thakur A., Rana M., Lakhanpal T. N., Ahmad A. and Khan M. I. 2007. Purification and characterization of lectin from fruiting body of *Ganoderma lucidum*: Lectin from *Ganoderma lucidum*. Biochimica et Biophysica Acta, 1770(9): 1404–1412.

Tomoda M., Gonda R., Kasahara Y. and Hikino H. 1986. Glycan structures of ganoderans B and C, hypoglycemic glycans of *Ganoderma lucidum* fruit bodies. Phytochemistry, 25(12): 2817–2820.

Unlu A., Nayir E., Kirca O. and Ozdogan M. 2016. *Ganoderma lucidum* (Reishi Mushroom) and cancer. Journal of the Balkan Union of oncolgy, 21(4): 792–798.

Upton R. 2000. American Herbal Pharmacopeia and Therapeutic Compendium: Reishi Mushroom, *Ganoderma lucidum*. Standards of Analysis, Quality Control, and Therapeutics. U.S.A. Canada: Santa Cruz. p.405-407.

Van Der Hem L., Van Der Vliet A., Bocken C. F. M., Kino K, Hoitsma A. J. and Tax W. J. M. 1995. Lingzhi-8: Studies of a new immunomodulating agent. Transplantation, 60(5): 438–443.

Wachtel-Galor S. and Benzie I.F.F. 2011. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press/Taylor and Francis, Chapter 1:p.1-10.

Wachtel-Galor S., Choi S. W. and Benzie I. F. F. 2005. Effect of *Ganoderma lucidum* on human DNA is dose dependent and mediated by hydrogen peroxide. Redox report: communications in free radical research, 10(3): 145–9.

Wachtel-Galor S., Szeto Y.T., Tomlinson B. and Benzie. F I. F. 2004. *Ganoderma lucidum* (Lingzhi): Acute and short-term biomarker response to supplementation.International Journal of food sciences and nutrition, 55(1): 75–83.

Wang H. and Ng T.B. 2006. Ganodermin, an antifungal protein from fruiting bodies of the medicinal mushroom *Ganoderma lucidum*. Peptides, 27(1): 27–30.

Wang H., Ng T.B. and Ooi V. E. C. 1998. Lectins from mushrooms. Mycological Research, 102(8): 897–906.

Wang Y. Y, Khoo K. H, Chen S. T, Lin C. C, Wong C. H and Lin C. H. 2002. Studies on the immunomodulating and antitumor activities of *Ganoderma lucidum* (Reishi) polysaccharides: Functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorganic and Medicinal Chemistry, 10(4):1057–1062.

Wasser S. P. and Weis A. L. 1999. Medicinal properties of substances occurring in higher basidiomycetes mushrooms: Current perspectives. International Journal of Medicinal Mushrooms, 1: 31–62.

Wasser S. P, Coates P., Blackman M., Cragg G., Levine M., Moss J. and White J 2005. Encyclopedia of Dietary Supplements. New York: Marcel Dekker; Reishi or Lingzhi (*Ganoderma lucidum*).p. 680–690.

Woo Y. A., Kim H. J., Cho J. H. and Chung H. 1999. Discrimination of herbal medicines according to geographical origin with near infrared reflectance spectroscopy and pattern
recognition techniques. Journal of Pharmaceutical and Biomedical Analysis, 21: 407–413.

Wu Y. and Wang D. 2009. A new class of natural glycopeptides with sugar moiety-dependent antioxidant activities derived from *Ganoderma lucidum* fruiting bodies. Journal of Proteome Research, 8: 436–42.

Zhao J. D. and Zhang X. Q. 1994. Importance, distribution and taxonomy of Ganodermataceae in China. Proceedings of Contributed Symposium, 5th International Mycological Congress, Vancouver. August 14-21.

Zhao L., Dong Y., Chen G. and Hu H. 2010. Extraction, purification, characterization and antitumor activity of polysaccharides from *Ganoderma lucidum*. Carbohydrate Polymers, 80(3): 783–789.

Zhang L., Zhang M. and Chen J. 2001. Solution properties of antitumor carboxymethylated derivatives of α-(1→3)-D-Glucan from *Ganoderma lucidum*. Chinese Journal of Polymorphic Science, 19:283–289.

Zhou X., Lin J., Yin Y., Zhao J., Sun X. and Tang K. 2007. Ganodermataceae: Natural products and their related pharmacological functions. The American journal of Chinese medicine, 35(4): 559–74.